山东大学学报 (医学版) ›› 2023, Vol. 61 ›› Issue (6): 29-40.doi: 10.6040/j.issn.1671-7554.0.2022.1373
• 基础医学 • 上一篇
刘娜1,王娜娜2,纪冰2,丁雪梅1,刘雅鑫1,房晓庆1,张晓丽1
LIU Na1, WANG Nana2, JI Bing2, DING Xuemei1, LIU Yaxin1, FANG Xiaoqing1, ZHANG Xiaoli1
摘要: 目的 调查住院老年患者感染病原菌分布及其耐药性变化趋势,为临床合理用药提供参考依据。 方法 收集2012年1月至2021年12月滨州医学院附属医院住院老年患者感染的病原菌,选用Cochran-Armitage趋势检验分析主要病原菌耐药率的年变化趋势。 结果 10年间共分离12 258株病原菌,革兰阴性菌占81.7%,最常见的是大肠埃希菌(19.7%);革兰阳性菌占18.3%,最常见的是金黄色葡萄球菌(5.7%)。22.5%的病原菌来自重症监护室,55.0%的病原菌分离自痰液标本。大肠埃希菌和肺炎克雷伯杆菌对碳青霉烯类抗菌药的耐药率在3%以下。10年间铜绿假单胞杆菌对碳青霉类抗菌药物的耐药率为10.2%~21.8%。鲍曼不动杆菌对碳青霉烯类抗菌药物的耐药率虽总体呈下降趋势,但2021年对其耐药率仍在40%以上。10年间耐甲氧西林金黄色葡萄球菌所占比为18.8%~44.7%,且期间检测到2株耐万古霉素的金黄色葡萄球菌和3株耐万古霉素的屎肠球菌。 结论 住院老年患者感染病原菌种类繁多且耐药形势不容乐观,医院应持续监测病原菌耐药情况,为临床合理应用抗菌药物提供科学依据。
中图分类号:
[1] European Centre for Disease Prevention and Control. Antibiotic resistance-an increasing threat to human health [EB/OL].(2018-11-18)[2022-11-20]. https://antibioti c.ecdc.europa.eu/en/publications-data/antibiotic-restance-increasing-threat-human-health-2018. [2] 游锦燕, 王素萍. 老年住院患者院内感染危险因素分析[J]. 中国卫生统计, 2020, 37(2): 281-283. YOU Jinyan, WANG Suping. Analysis of risk factors for nosocomial infection in elderly hospitalized patients [J]. Health Statistics of China, 2020, 37(2): 281-283. [3] 刘金花, 徐志云, 徐晓蓉. 呼吸科院内老年人感染病原菌分布及耐药性[J].中国老年学杂志, 2022, 42(7): 1697-1699. LIU Jinhua, XU Zhiyun, XU Xiaorong. Distribution and drug resistance of the people in the respiratory hospital [J]. Chinese Journal of Gerontology, 2022, 42(7): 1697-1699. [4] Khadka S, Khan S, King A, et al. Poor oral hygiene, oral microorganisms and aspiration pneumonia risk in older people in residential aged care: a systematic review [J]. Age Ageing, 2021, 50(1): 81-87. [5] 王晓宁, 景双艳, 魏莲花. 2018年甘肃省64所医院老年患者临床分离菌耐药性监测[J].中国感染与化疗杂志, 2020, 20(5): 540-545. WANG Xiaoning, JING Shuangyan, WEI Lianhua. Antimicrobial resistance surveillance in the clinical strains isolated from elderly patients in 64 hospitals in Gansu Province during 2018 [J]. Chinese Journal of Infection and Chemotherapy, 2020, 20(5): 540-545. [6] Ardoino I, Mannucci PM, Nobili A, et al. REPOSI Collaborators. Antibiotic use and associated factors in a large sample of hospitalised older people [J]. J Glob Antimicrob Resist, 2019, 19: 167-172. doi: 10.1016/j.jgar.2019.04.013. [7] Wang C, Li W, Gao J, et al. Microbial predominance and antimicrobial resistance in a tertiary hospital in Northwest China: a six-year retrospective study of outpatients and patients visiting the emergency department [J]. Can J Infect Dis Med Microbiol, 2020, 2020: 883-847. doi: 10.1155/2020/8838447. [8] Dadashi M, Sameni F, Bostanshirin N, et al. Global prevalence and molecular epidemiology of mcr-mediated colistin resistance in escherichia coli clinical Isolates: a systematic review [J]. J Glob Antimicrob Resist, 2022, 29: 444-461. doi: 10.1016/j.jgar.2021.10.022. [9] Pulingam T, Parumasivam T, Gazzali AM, et al. Antimicrobial resistance: prevalence, economic burden, mechanisms of resistance and strategies to overcome [J]. Eur J Pharm Sci, 2022, 170: 106103. doi: 10.1016/j.ejps.2021.106103. [10] 全国细菌耐药监测网. 全国细菌耐药监测网2014—2019年老年患者常见临床分离细菌耐药性监测报告[J]. 中国感染控制杂志, 2021, 20: 112-123. [11] Mahendra M, Jayaraj BS, Lokesh KS, et al. Antibiotic prescription, organisms and its resistance pattern in patients admitted to respiratory ICU with respiratory infection in mysuru [J]. Indian J Crit Care Med, 2018, 22(4): 223-230. [12] Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections [J]. Clin Infect Dis, 2019, 69(Suppl 7): S565-S575. doi: 10.1093/cid/ciz830. [13] 刘可可, 徐华, 孙建, 等. 2019-2020年山东省医院感染监测网细菌监测报告[J]. 中华医院感染学杂志, 2022, 32(6): 920-924. LIU Keke, XU Hua, SUN Jian, et al. Bacteria surveillance report of 2019 and 2020 based on Shandong Province nosocomial infection surveillance network [J]. Chinese Journal of Nosocomiology, 2022, 32(6): 920-924. [14] 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组, 中国医药教育协会感染疾病专业委员会, 中华医学会细菌感染与耐药防控专业委员会. 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志, 2021, 101(36): 2850-2860. China expert consensus writing group on diagnosis and Treatment and prevention of carbapenem-resistant Enterobacteriaceae Infection, Infectious Diseases Committee of China Medical Education Association, Professional Committee of Bacterial Infection and Resistance Prevention and Control of Chinese Medical Association. Expert consensus on diagnosis and treatment and prevention of carbapenem-resistant Enterobacteriaceae in China [J]. Chinese Journal of Medicine, 2021, 101(36): 2850-2860. [15] Ayoub Moubareck C, Hammoudi Halat D. Insights into acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen [J]. Antibiotics(Basel), 2020, 9(3): 119. doi: 10.3390/antibiotics9030119. [16] 胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21: 377-387. HU Fupin, GUO Yan, ZHU Demei, et al. CHINET surveillance of bacterial resistance: results of 2020 [J]. Chinese Journal of Infection and Chemotherapy, 2021, 21: 377-387. [17] 李可可, 邹凤梅, 杨永清, 等. 2009—2019年甘肃省人民医院血流感染病原菌分布及耐药性分析[J]. 中国抗生素杂志, 2022(8): 834-838. LI Keke, ZOU Fengmei, YANG Yongqing, et al. Distribution of pathogenic bacteria and analysis of drug resistance in blood flow infection in gansu provincial hospital from 2009 to 2019 [J]. Chinese Journal of Antibiotics, 2022(8): 834-838. [18] Kurihara MNL, Sales RO, Silva KED, et al. High lethality rate of carbapenem-resistant acinetobacter baumannii in Intensive care units of a Brazilian hospital: An epidemiologic surveillance study [J]. Rev Soc Bras Med Trop, 2022, 55: e05292021. doi: 10.1590/0037-8682-0529-2021. [19] Granata G, Taglietti F, Schiavone F, et al. Durlobactam in the treatment of multidrug-resistant acinetobacter baumannii infections: a systematic review [J]. J Clin Med, 2022, 11(12): 3258. [20] Palavecino E, Greene SR, Kilic A. Characterisation of carbapenemase genes and antibiotic resistance in carbapenem-resistant Acinetobacter baumannii between 2019 and 2022 [J]. Infect Dis(Lond), 2022, 54(12): 951-953. [21] 黎昆, 王芬, 王洁, 等. 2018—2020年四川遂宁市中心医院细菌耐药性监测[J]. 中国感染与化疗杂志, 2022, 22(1): 78-84. LI Kun, WANG Fen, WANG Jie, et al. Surveillance of bacterial resistance in Suining Central Hospital of Sichuan in a 3-year period from 2018 to 2020 [J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(1): 78-84. [22] 何秀华, 朱焱, 杨鹏雅, 等. 2018—2020年泉州市第一医院细菌耐药性监测[J]. 中国感染与化疗杂志, 2022, 22(4): 454-462. HE Xiuhua, ZHU Yan, YANG Pengya, et al. Surveillance of bacterial resistance in Quanzhou Municipal First Hospital from 2018 to 2020 [J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(4): 454-462. [23] Huang G, Lai W, Wu D, et al. Two cases report of intrathecal tigecycline therapy for intracranial infection with Acinetobacter baumannii and review of literatures [J]. Infect Drug Resist, 2022, 15: 2211-2217. doi: 10.2147/IDR.S357087. [24] Srikanth D, Joshi SV, Ghouse Shaik M, et al. A comprehensive review on potential therapeutic inhibitors of nosocomial acinetobacter baumannii superbugs [J]. Bioorg Chem, 2022, 124: 105849. doi: 10.1016/j.bioorg.2022.105849. [25] 杨启文, 吴安华, 胡必杰, 等. 临床重要耐药菌感染传播防控策略专家共识[J]. 中国感染控制杂志, 2021, 20(1): 1-14. YANG Qiwen, WU Anhua, HU Bijie, et al. Expert consensus on strategies for the prevention and control of spread of clinically important antimicrobial-resistant organisms [J]. Chinese Journal of Infection Control, 2021, 20(1): 1-14. [26] Viswanath LS, Sugumar M, Chandra Murthy Peela S, et al. Detection of vancomycin variable enterococci(VVE)among clinical isolates of Enterococcus faecium collected across India-first report from the subcontinent [J]. Indian J Med Microbiol, 2022, 40(2): 285-288. [27] Chaguza C, Yang M, Jacques LC, et al. Serotype 1 pneumococcus: epidemiology, genomics, and disease mechanisms [J]. Trends Microbiol, 2022, 30(6): 581-592. [28] 中华预防医学会, 中华预防医学会疫苗与免疫分会. 肺炎球菌性疾病免疫预防专家共识(2017版)[J]. 中华流行病学杂志, 2018, 39(2): 111-138. Chinese Preventive Medicine Association, Vaccine and Immunology Branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease(2017 version)[J]. Chinese Journal of Epidemiology, 2018, 39(2): 111-138. |
[1] | 安袁笑雪,杜以明,田甜,张一,薛玉文. 肺炎奴卡菌合并天美奴卡菌肺部感染1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 59-63. |
[2] | 李燕,刘静,李娟,杨秋红. 50例孕产妇血流感染临床特征及胎盘病理分析[J]. 山东大学学报 (医学版), 2022, 60(1): 48-54. |
[3] | 鞠建华,杨镇业,李青连,韩亚楠,李艳青,乔伊君,杨虎,张华然. 微生物药物研究开发现状与思考[J]. 山东大学学报 (医学版), 2021, 59(9): 43-50. |
[4] | 赵立红,赵书平,聂升刚,孙晶,姜同峰. 507例男性生殖道感染病原体分布及耐药特征[J]. 山东大学学报 (医学版), 2021, 59(1): 55-58. |
[5] | 杨夏鑫,孟明珠,纪坤乾,王晓棠,童丽丽,王爱芹,赵秀鹤. 线粒体脑肌病伴高乳酸血症和卒中样发作中癫痫发作的临床特征[J]. 山东大学学报 (医学版), 2018, 56(5): 74-80. |
[6] | 崔毅,尹梅,李伟,李远,韩辉,单悌超,岳金凤,丁士芳,李琛,陈晓梅,吴大玮,王昊. 山东大学齐鲁医院金黄色葡萄球菌血流感染发生率、菌株耐药性、抗菌药物使用及预后变化[J]. 山东大学学报 (医学版), 2018, 56(12): 33-38. |
[7] | 杨丁,杨鹏,李玉波,孙强. 基于面板数据的村卫生室上呼吸道感染处方用药变化规律——以山东省Z县8个村卫生室为例[J]. 山东大学学报 (医学版), 2017, 55(12): 88-94. |
[8] | 娄婷叶, 张永春. 4年间铜绿假单胞菌医院感染分布及耐药性变迁[J]. 山东大学学报(医学版), 2014, 52(S2): 39-41. |
[9] | 张淑红, 刘红敏, 赵洪方. 中段尿培养的病原菌分布及耐药分析[J]. 山东大学学报(医学版), 2014, 52(S1): 114-115. |
[10] | 郭爱萍1,于秀娟2,刘新风1,王德景1,郑文1. 3598株临床分离病原菌的分布及耐药性[J]. 山东大学学报(医学版), 2013, 51(7): 87-91. |
[11] | 张成梅1,武传涛1,朱珊珊2,贾舒3,王一4,史艳秋1,2. 新骨架小分子南强菌素对紫杉醇耐药性的逆转作用及其机制[J]. 山东大学学报(医学版), 2013, 51(4): 21-25. |
[12] | 王海滨,马伟明,萧畔,马天加,张怀强. 热休克蛋白60在多西紫杉醇治疗激素非依赖性前列腺癌过程中的差异表达[J]. 山东大学学报(医学版), 2012, 50(8): 46-50. |
[13] | 张敬敬1,王哲1,田永杰1,张捷2. PJ34对卵巢癌C13*细胞生长活性及耐药性的影响[J]. 山东大学学报(医学版), 2012, 50(1): 46-50. |
[14] | 高超1,2,胡明2,白华2,齐静2,朱小玲2,刘昌彬3,. 铜绿假单胞菌对环丙沙星的抗药性和耐药性机制研究[J]. 山东大学学报(医学版), 2011, 49(6): 38-45. |
[15] | 王开雷,李乐平,靖昌庆. 两种人大肠癌多药耐药株的建立及耐药性比较[J]. 山东大学学报(医学版), 2011, 49(4): 75-. |
|